20.74USD+2.52%Mkt Cap: 571.90M USDP/E: —Last update: 2026-05-22
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VE…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap571.90M USD
Enterprise Value488.60M USD
Revenue (TTM)11.88M USD
Gross Profit11.88M USD
Net Income (TTM)-153.94M USD
Revenue/Share0.5900 USD
Last Price20.74 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINIE0004LIBFM2
Valuation
P/E (Trailing)—
P/E (Forward)-6.87
PEG—
EV/EBITDA—
EV/Revenue41.12
P/S46.94
P/B3.74
EPS (TTM)-5.88
EPS (Forward)-2.94
52W Range
8.72064% of range27.41
52W High27.41 USD
52W Low8.720 USD
Profitability
Gross Margin100.00%
Oper. Margin-2380.08%
EBITDA Margin0.00%
Profit Margin-1419.61%
ROE-75.83%
ROA-64.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.53M USD
CapEx (TTM)72.92M USD
FCF Margin—
FCF Yield—
Net Debt-187.62M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio13.78
Quick Ratio13.33
Book Value/Sh5.412 USD
Cash/Share5.693 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJun 16, 2025
Analyst Consensus
Rating—
Target (Mean)30.29 USD
Target Range22.00 USD – 35.00 USD
# Analysts7
Ownership
Shares Out.27.57M
Float14.60M
Insiders5.81%
Institutions96.16%
Short Interest
Short Ratio9.0d
Short % Float19.84%
Short % Out.8.69%
Shares Short2.40M
Short (prev mo.)2.24M
Technical
SMA 5018.09 (+14.7%)
SMA 20013.80 (+50.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)300.28K
Avg Vol (10d)267.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—